Octreotide scan

Octreotide scan
Diagnostics

111In-pentetreotide scintigraphy of the 41-year-old man with ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery. Radiotracer accumulation in the left thyroid in 10/2003 (arrow). The mesenterial neuroendocrine tumor became clearly visible in 4/2005 (arrow).
ICD-9-CM 92.18
OPS-301 code 3-70c

An octreotide scan or octreoscan is a type of scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111,[1] and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A radiation-measuring device detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body.

It is also called somatostatin receptor scintigraphy and SRS.

Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors.[2]

See also

Krenning score

References

  1. ↑ medicinenet.com > Carcinoid Syndrome (cont.) By Dennis Lee and Jay Marks. Retrieved Mars 2011
  2. ↑ Kwekkeboom, DJ; Krenning, EP (April 2002). "Somatostatin receptor imaging.". Seminars in nuclear medicine 32 (2): 84–91. doi:10.1053/snuc.2002.31022. PMID 11965603.

External links

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".


This article is issued from Wikipedia - version of the Sunday, March 13, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.